BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34855239)

  • 1. Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Arcot R; Cher ML; Qi J; Linsell SM; Dunn RL; George AK; Montie JE; Ginsburg KB;
    Prostate; 2022 Feb; 82(3):323-329. PubMed ID: 34855239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
    Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
    Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate versus delayed prostatectomy: Nationwide population-based study (.).
    Loeb S; Folkvaljon Y; Robinson D; Makarov DV; Bratt O; Garmo H; Stattin P
    Scand J Urol; 2016 Aug; 50(4):246-54. PubMed ID: 27067998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance.
    Mallya A; Senguttuvan-Karthikeyan V; Sivaraman A; Barret E; Galiano M; Cathala N; Mombet A; Prapotnich D; Sanchez-Salas R; Cathelineau X
    Actas Urol Esp (Engl Ed); 2019; 43(6):324-330. PubMed ID: 30928176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    Paudel R; Madan R; Qi J; Ferrante S; Cher ML; Lane BR; George AK; Semerjian A; Ginsburg KB
    J Urol; 2023 Jan; 209(1):170-179. PubMed ID: 36265120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
    Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
    BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
    Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
    Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
    Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
    Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38057193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
    Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
    Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    Chappidi MR; Bell A; Cowan JE; Greenberg SA; Lonergan PE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    J Urol; 2022 May; 207(5):1001-1009. PubMed ID: 34981949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
    Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
    J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
    BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy.
    Auffenberg GB; Linsell S; Dhir A; Myers SN; Rosenberg B; Miller DC;
    J Urol; 2016 Nov; 196(5):1415-1421. PubMed ID: 27256204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.